CA 19.9, CA 242 and CEA in the Diagnosis and Follow-up of Pancreatic Cancer

Banfi, Giuseppe; Bravi, Stefano; Ardemagni, A.; Zerbi, Alessandro

doi:10.1177/172460089601100203

Cited by 21 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results were promising and CA 242 has shown sensitivities and specficities similar to those of CA 19-9 and CA 50. For this study we colklcte a large series of 179 patients with pancreatic cancer, enabling Our study confirms previous obsations that the assay parameters of CA 242 are similar to those of CA 19-9 in the primary diagnosis of pancreatic cancer (Kuusela et al, 1991;Banfi et al, 1993;R6thlin et al, 1993). The highest serum levels of CA 242 and CA 19-9 were found in patients with unresectable dies, which can be diagnosed by other clinical, radiological and laboratory investigations rather easily.…”

Section: Ca 242 In Benign Diseasessupporting

confidence: 85%

“…Preliminary results on the serum expression of CA 242 in pancreatic cancer were described in 1991 by Kuusela et al Later other small series including 24-68 patients were reported (Nilsson et al, 1992;Pasanen et al, 1992;Banfi et al, 1993;R6thlin et al, 1993). The results were promising and CA 242 has shown sensitivities and specficities similar to those of CA 19-9 and CA 50.…”

Section: Ca 242 In Benign Diseasesmentioning

confidence: 92%

See 1 more Smart Citation

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

Haglund

Lundin²,

Kuusela³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensitivity of the CA 242 assay was 74%: 55% in stage I, 83% in stage II-III and 78% in stage IV disease. The specificity calculated from 112 patients with benign diseases was 91%. CA 19-9 had a higher sensitivity of 83%, but the specificity was only 81%. When comparing the markers by receiver operating characteristic analysis, the sensitivities were almost identical at all specificity levels. The CA 242 level was elevated in 7%, 15% and 7% of patients with benign pancreatic, biliary and liver disease respectively. The corresponding figures for CA 19-9 were 19%, 28% and 15% respectively. The sensitivity of CA 242 was higher than that of CA 50 and CEA at all specificity levels. In conclusion, tumour marker CA 242 seems to be a useful diagnostic tool for the diagnosis of pancreatic cancer, and is an alternative to CA 19-9. The advantage of CA 242 over CA 19-9 is its higher specificity when using the recommended cut-off levels of the assays.

show abstract

Section: Ca 242 In Benign Diseasessupporting

confidence: 85%

Section: Ca 242 In Benign Diseasesmentioning

confidence: 92%

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

Haglund

Lundin²,

Kuusela³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…It is worth noting, how ever, that the specificity of TPS was consider ably higher (73%). To some extent, our results are in contrast to those of Banfi et al [8] who found TPS highly sensitive (97.8%), but not specific (22%) among benign pancreatic dis eases. In that study, the cutoff level for TPS (40 U/l) was determined in healthy subjects using the 95th percentile.…”

Section: Discussioncontrasting

confidence: 56%

“…In the literature, few data are available on the utility of serum TPA and TPS assays in the diagnosis of pancreatic cancer. The sensitivity of TPA has varied from 36 to 96% and the specificity from 67 to 92% [5][6][7], and the sensitivity of TPS was found to be 97.8% and the specificity between 22 and 88% [8]. Lack of specificity has been one of the problems in the use of the serum tumor mark ers in pancreatic cancer [9][10][11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Tissue Polypeptide Specific Antigen in Patients with Pancreatic Carcinoma

Pasanen

Eskelinen²,

Partanen³

et al. 1994

Tumor Biol

View full text Add to dashboard Cite

We evaluated the clinical utility of a new tumor marker tissue polypeptide specific antigen (TPS) in the diagnosis of pancreatic carcinoma. Serum concentrations were determined in 113 patients with jaundice, in 18 patients with laboratory values suggesting cholestasis and in 60 patients with suspicion of chronic pancreatitis or pancreatic tumor. Twenty-four of these 191 patients had pancreatic carcinoma and 2 patients had carcinoma of the papilla of Vater. The highest median serum TPS value was detected in patients with malignant liver disease, but high median values were also measured in patients with pancreatic cancer, bile duct cancer or benign liver disease. The sensitivity of TPS was 50.0%, with a specificity of 73% and an efficiency of 70%. In comparison with carcinoembryonic antigen (CEA), CA 50 and CA 242, the TPS test showed lower sensitivity, but the differences in specificity and negative predictive value were considerably smaller. The utility of TPS as a complementary test was also analyzed. When TPS was combined with other marker tests, their specificities clearly improved, being highest in the combination of TPS and CA 242 (92.5%). In this combination, efficiency and positive likelihood ratio were also clearly better (85% and 5.6) than those of the marker tests alone. In conclusion, TPS seems less accurate than CEA, CA 50 or CA 242 in the diagnosis of pancreatic cancer, but because of its different nature it may be considered to be used as a complementary test.

show abstract

“…In some studies CA 19-9 has been found to be superior to TPS (16)(17)(18), whereas in another study the contrary was shown (19). We found that the AUC was slightly higher for TPS than for CA19-9 and CEA, but the differences were not significant.…”

Section: Discussioncontrasting

confidence: 42%

TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head

Sandblom

Granroth

Rasmussen

2008

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Introduction: Although numerous tumour markers are available for periampullary tumours, including pancreatic cancer, their specificity and sensitivity have been questioned. Materials and methods:To assess the diagnostic and prognostic values of tissue polypeptide specific antigen (TPS), carbohydrate antigen 19-9 (CA 19-9), vascular endothelial growth factor (VEGF-A), and carcinoembryonic antigen (CEA) we took serum samples in 56 patients with mass lesions in the pancreatic head. Among these patients, further investigations revealed pancreatic cancer in 20 patients, other malignant diseases in 12 and benign conditions in 24.Results: Median CEA in all patients was 3.4 μg/L (range 0.5-585.0), median CA 19-9 was105 kU/L (range 0.6-1 300 00), median TPS 123.5 U/L (range 15.0-3350) and median VEGF-A 132.5 ng/L (range 60.0-4317). Area under the curve was 0.747, standard error (standard error [SE] =0.075) for CEA, 0.716 (SE=0.078) for CA 19-9 and 0.822 (SE=0.086) for TPS in ROC plots based on the ability of the tumours to distinguish between benign and malignant conditions. None of the markers significantly predicted survival in the subgroup of patients with pancreatic cancer. Discussion: Our study shows that the markers may be used as fairly reliable diagnostic tools, but cannot be used to predict survival.

show abstract

CA 19.9, CA 242 and CEA in the Diagnosis and Follow-up of Pancreatic Cancer

Cited by 21 publications

References 23 publications

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

Diagnostic Value of Tissue Polypeptide Specific Antigen in Patients with Pancreatic Carcinoma

TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head

Contact Info

Product

Resources

About